Modern Chinese Medicine Group Co. Ltd. (HK:1643)
:1643
Want to see HK:1643 full AI Analyst Report?
1643 Stock Chart & Stats
HK$0.51
<HK$0.01(1.54%)
At close: 4:00 PM EST
HK$0.51
<HK$0.01(1.54%)
Day’s Range― - ―
52-Week RangeHK$0.31 - HK$3.26
Previous CloseN/A
Volume456.00K
Average Volume (3M)639.13K
Market Cap
HK$2.01B
Enterprise ValueHK$1.50B
Total Cash (Recent Filing)HK$229.81M
Total Debt (Recent Filing)HK$69.03K
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding720,000,000
10 Day Avg. Volume382,100
30 Day Avg. Volume639,133
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.61
Price to Sales (P/S)2.14
P/FCF Ratio-18.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low debt gives the company durable financial flexibility to fund operations, absorb cyclical revenue shocks, and pursue selective investments or M&A without refinancing risk. Low leverage materially lowers solvency risk and supports resilience over a multi-month horizon.
Positive Operating Cash Flow CapabilityThe firm's ability to generate positive operating cash flow even amid a loss year shows underlying cash generation in core operations. This supports working capital, stabilizes liquidity across cycles, and provides a foundation for restoring investment and margins as demand normalizes.
Demonstrated Historical ProfitabilityPrior multi-year profitability indicates the business model and product economics can achieve healthy margins under normal demand. That historical track record suggests operational know-how, scalable production and pricing levers that can restore returns when market conditions improve.
Bears Say
Sharp Revenue DeclineA ~30% revenue drop materially reduces scale economics and market presence. Persistent top-line erosion undermines fixed-cost coverage and raises the risk of lost distribution/customer relationships, making recovery of prior margins and EBITDA levels a multi-quarter challenge.
Profitability Swing To Net LossSwitching to a net loss and compressed gross margins signals structural pressure on pricing, mix, or cost control. This reduces retained earnings and limits internal reinvestment capacity, raising execution risk for product development, marketing, and margin restoration over the coming months.
Negative Free Cash Flow & VolatilityRecent negative free cash flow despite positive operating cash flow points to higher capex, working capital strain or weak cash conversion. Persistent FCF deficits constrain growth funding and may force use of cash reserves or asset sales, pressuring operational options over 2–6 months.
Modern Chinese Medicine Group Co. Ltd. News
1643 FAQ
What was Modern Chinese Medicine Group Co. Ltd.’s price range in the past 12 months?
Modern Chinese Medicine Group Co. Ltd. lowest stock price was HK$0.31 and its highest was HK$3.26 in the past 12 months.
What is Modern Chinese Medicine Group Co. Ltd.’s market cap?
Modern Chinese Medicine Group Co. Ltd.’s market cap is HK$2.01B.
When is Modern Chinese Medicine Group Co. Ltd.’s upcoming earnings report date?
Modern Chinese Medicine Group Co. Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 89 days.
How were Modern Chinese Medicine Group Co. Ltd.’s earnings last quarter?
Modern Chinese Medicine Group Co. Ltd. released its earnings results on Mar 30, 2026. The company reported -HK$0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.027.
Is Modern Chinese Medicine Group Co. Ltd. overvalued?
According to Wall Street analysts Modern Chinese Medicine Group Co. Ltd.’s price is currently Overvalued.
Does Modern Chinese Medicine Group Co. Ltd. pay dividends?
Modern Chinese Medicine Group Co. Ltd. pays a Notavailable dividend of HK$0.017 which represents an annual dividend yield of N/A. See more information on Modern Chinese Medicine Group Co. Ltd. dividends here
What is Modern Chinese Medicine Group Co. Ltd.’s EPS estimate?
Modern Chinese Medicine Group Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modern Chinese Medicine Group Co. Ltd. have?
Modern Chinese Medicine Group Co. Ltd. has 720,000,000 shares outstanding.
What happened to Modern Chinese Medicine Group Co. Ltd.’s price movement after its last earnings report?
Modern Chinese Medicine Group Co. Ltd. reported an EPS of -HK$0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.013%.
Which hedge fund is a major shareholder of Modern Chinese Medicine Group Co. Ltd.?
Currently, no hedge funds are holding shares in HK:1643
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Modern Chinese Medicine Group Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.59%
12-Months-Change
Fundamentals
Return on Equity
-2.70%
Trailing 12-Months
Asset Growth
5.26%
Trailing 12-Months
Company Description
Modern Chinese Medicine Group Co. Ltd.
Modern Chinese Medicine Group Co., Ltd., an investment holding company, produces and sells proprietary Chinese medicines for elderlies and aged-middle in the People's Republic of China. It offers therapeutics for the qi-deficiency and blood-statis, cardio-cerebrovascular, digestive and gastrointestinal, gynecological, respiratory system, and nervous system conditions. The company was founded in 1986 and is headquartered in Chengde, China. Modern Chinese Medicine Group Co., Ltd. is a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.
Technical Analysis
Tong Ren Tang Technologies Co
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―